# Murtaza Mussaji, D.O.. – FDA 483, Aug 28, 2026

Source: https://www.keypedia.com/records/483/murtaza-mussaji-do/15e6be7a-71a9-4980-9476-a1619c6ac603

> FDA 483 for Murtaza Mussaji, D.O.. on August 28, 2026. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Murtaza Mussaji, D.O..
- Inspection Date: 2026-08-28
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Summary: An FDA inspection of Murtaza Mussaji, D.O., a clinical investigator in Pearland, TX, revealed a significant issue regarding the conduct of an investigation. The firm failed to adhere to the signed statement of investigator and investigational plan, specifically by not making timely contact with a subject following multiple safety alerts for worsening symptoms. This indicates a serious lapse in patient monitoring and protocol adherence during a clinical trial.

## Related Officers

- [Ruth E. Medcalf](https://www.keypedia.com/people/ruth-e-medcalf/71a61d32-807b-4b73-9ea7-b59287e14e56)

Company: https://www.keypedia.com/companies/murtaza-mussaji-do/a01b5e77-00db-4583-93a3-4fc2548b4d20

Office: https://www.keypedia.com/offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c